Disease Landscape and Forecast Insights

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts of key endometrial carcinoma patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of cancer pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

In the United States, osteoarthritic pain affects about 32 million people; an aging population and the increasing prevalence of obesity are predicted to fuel additional growth. Several treatment…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…

Clarivate Epidemiology’s coverage of the meningococcal ACWY vaccine comprises epidemiological estimates of key patient populations in major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of the influenza vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. Treatments are needed that can…

Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…

Heart failure with reduced ejection fraction (HFrEF) has a well-established drug treatment with a wealth of supporting evidence from clinical trials. ACE inhibitors, or ARBs, beta blockers, and…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases, and even though understanding of the disease’s pathophysiology has…